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INVENTORY OF SUPPLEMENTARY INFORMATION Supplementary Figures and Figure Legends S1 through S11
. Separation of population-based effects using stem and progenitor cell data from primary CML patients. Supplementary Tables S1 through S2 Table S1 GO Enrichment analysis of genes differentially up-regulated between early and late CP CML. Table S2 . GO Enrichment analysis of genes differentially down-regulated between early and late CP CML.
Supplementary Table Legends
Supplementary Resources and Methods Equally, simulation of entropy of cell population mixing throughout hematopoietic evolution (mixing entropy, lower curve) shows a singular maximum point that coincides with the minimum of gene expression entropy derived from the model. Figure S11 The number of active HSCs is not increased in CML and is estimated to remain indicates the rate at which cells originating in compartment i -1 enter compartment i .
In the event of a cancer mutation in the HSC compartment, healthy HSCs are
whereas for CML cells ( ! !"# ) we consider !"# < ! , indicating a lower probability of differentiation in CML. Starting with one single CML HSC, disease expansion, assessed at hands of the growth of the BCR-ABL/BCR ratio, takes almost 6 years until it becomes clinically evident at !"# = 0.72 (>10 12 cells bone marrow output).
Hematopoietic cell sub-populations
Gene expression and principal component analyses (PCA) related to -30% blasts or < 10% blasts with clonal evolution (additional cytogenetic changes), and BC > 30% blasts 5, 6 . Patients in CP with no available blast count were assigned 20 blast count = 1. The dataset includes normal CD34 + enriched cells as control samples, which we considered in our analysis ( Supplementary Fig. S2 online).
Bootstrapping analyses
Supplementary Figure S5 :
Significance of the p value for the correlation between simulated and clinically observed entropy of gene expression was challenged through 1,000 iterations of random sub-sampling, removing 10% of data points in each iteration without replacement, and calculating the p value of the resulting correlation on the remaining 90% of data points. Resulting p value frequencies for 1,000 iterations are indicated.
Supplementary Figures S9 and S10:
The fractions (%) of genes differentially expressed between CML disease stages (see Supplementary Figure S8 ) were identified at a cut-off of p < 0.05 (FDR-adjusted p value) and significance of differential expression was assessed by 2-sided t-test as described in the methods section accompanying this manuscript (MATLAB statistical toolbox). To assess robustness of the fractions of differentially expressed genes identified between the CML disease stages using this approach, random subsampling considering 90% of the patient cohort was performed at 1,000 iterations.
Frequencies of fractions of differentially expressed genes identified across all iterations at p < 0.05 (FDR-adjusted p value) are shown and the mean and associated standard deviation (ST.DEV) were determined. The same methodology was applied to simulate effect of changes in patient cohort size on the mean fraction of genes differentially expressed between CML chronic phase (T1-CP) and blast crisis (BC). To this end, random sub-sampling at 1,000 iterations across patient cohorts reduced in size by discrete increments of 10% were performed, each time considering the remaining 90% of patients to determine the fractions (%) of genes differentially expressed genes. Corresponding mean fractions of differentially expressed genes and associated ST.DEV were identified accordingly.
